A 2022 study noted that an IL-6/IL-10 mRNA expression signature in breast tumors was paradoxically linked to better survival in early-stage patients, hypothesizing that some level of immune activation (IL-6) combined with IL-10-mediated resolution might be beneficial [35]. Here, IL6 is linked to breast neoplasm.